Dewpoint congratulates its co-founder Tony Hyman, for receiving the NOMIS Foundation’s Distinguished Scientist and Scholar Award.  The award recognises outstanding contributions […]

Dewpoint Therapeutics co-founder Anthony Hyman will share the 2020 Wiley Prize in Biomedical Sciences for his foundational work on biomolecular […]

The announcement of Dewpoint Therapeutics $100M partnership Bayer to research new treatments for cardiovascular and gynecological diseases has received significant […]

BERLIN / BOSTON, November 14, 2019 – Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, […]

Dewpoint congratulates our scientific founder, Richard Young, on being named to the National Academy of Medicine.

BERLIN / BOSTON, September 23, 2019 –  Rounding out a year of tremendous growth on two continents, Dewpoint Therapeutics, the biomolecular condensates company, has […]

The announcement of the launch of Dewpoint Therapeutics, with $60 Million Series A funding has received significant attention from media […]

CAMBRIDGE, Mass. January 30, 2019 – Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched […]

In June 2024, Lis Leiderman, M.D., MBA joined Dewpoint’s Executive Leadership Team as Chief Financial and Corporate Development Officer. With […]

At Dewpoint, we are working to unlock the full potential of condensate science to discover and develop life-changing treatments for […]

At Dewpoint we are embracing all forms of science from biology, chemistry and physics to data science and artificial intelligence […]

“I believe we are on our way towards a MYC c-mod, says Bede Portz, Dewpoint’s ovarian cancer program lead. Our […]